TPST Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.3M
-81.1%
27.7M
+579.9%
4.1M
+13.3%
3.6M
-54.8%
8.0M
R&D
1.8M
-91.8%
22.3M
+4036.2%
539.0K
-5.4%
570.0K
-85.3%
3.9M
SG&A
3.4M
-36.8%
5.4M
+53.3%
3.5M
+16.9%
3.0M
-26.1%
4.1M
Operating Income
-5250000
+81.1%
-27719000
-579.9%
-4077000
-13.3%
-3597000
+54.8%
-7966000
EBITDA
-5190000
+81.2%
-27659000
-589.4%
-4012000
-13.6%
-3531000
+55.3%
-7899000
Net Income
-5244000
+81.1%
-27696000
-588.8%
-4021000
-14.5%
-3511000
+55.4%
-7870000
EPS (Basic)
$-0.34
+86.6%
$-2.53
-208.5%
$-0.82
-3.8%
$-0.79
+61.8%
$-2.07
EPS (Diluted)
$-0.34
+86.6%
$-2.53
-208.5%
$-0.82
-3.8%
$-0.79
+61.8%
$-2.07
Shares (Diluted)
15.2M
+39.3%
10.9M
+122.3%
4.9M
+10.8%
4.4M
+16.8%
3.8M
Tempest Therapeutics (TPST) โ€” Financials